Read More Pharma Industry News Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema. byPallavi MadhirajuMay 7, 2025